WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555343
Description: GLX351322 is a NADPH oxidase 4 inhibitor. GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. GLX351322 inhibits hydrogen peroxide production from tetracycline inducible NOX4-overexpressing cells with IC50 of 5 uM.
MedKoo Cat#: 555343
Chemical Formula: C21H25N3O5S
Exact Mass: 431.1515
Molecular Weight: 431.51
Elemental Analysis: C, 58.45; H, 5.84; N, 9.74; O, 18.54; S, 7.43
Synonym: GLX351322; GLX-351322; GLX 351322
IUPAC/Chemical Name: Ethyl 2-[[2-[4-(furan-2-carbonyl)piperazin-1-yl]acetyl]amino]-5,6-dihydro-4H-cyclopenta-[b]thiophene-3-carboxylate
InChi Key: KEVHLTCEMHIJTQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H25N3O5S/c1-2-28-21(27)18-14-5-3-7-16(14)30-19(18)22-17(25)13-23-8-10-24(11-9-23)20(26)15-6-4-12-29-15/h4,6,12H,2-3,5,7-11,13H2,1H3,(H,22,25)
SMILES Code: O=C(C1=C(NC(CN2CCN(C(C3=CC=CO3)=O)CC2)=O)SC4=C1CCC4)OCC
In type 2 diabetes, it has been proposed that pancreatic beta-cell dysfunction is promoted by oxidative stress caused by NADPH oxidase (NOX) overactivity. Five different NOX enzymes (NOX1-5) have been characterized, among which NOX1 and NOX2 have been proposed to negatively affect beta-cells, but the putative role of NOX4 in type 2 diabetes-associated beta-cell dysfunction and glucose intolerance is largely unknown
1: Wang X, Elksnis A, Wikström P, Walum E, Welsh N, Carlsson PO. The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitro. PLoS One. 2018 Sep 28;13(9):e0204271. doi: 10.1371/journal.pone.0204271. eCollection 2018. PubMed PMID: 30265686; PubMed Central PMCID: PMC6161897.
2: Anvari E, Wikström P, Walum E, Welsh N. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. Free Radic Res. 2015;49(11):1308-18. doi: 10.3109/10715762.2015.1067697. Epub 2015 Jul 30. PubMed PMID: 26118714.